David Nierengarten Re-evaluates JUNO; Upgrades Shares to Outperform
Following a KOL discussion of Car-T therapies coupled with this week’s encouraging clinical update on the ZUMA-1 trial in Non-Hodgkin’s lymphoma (LMA), top …
Novan Inc (NASDAQ:NOVN) stock torpedoed on Friday after the biotech firm’s lead pipeline drug for the treatment of acne vulgaris failed its Phase …
On October 13th, bluebird bio Inc (NASDAQ:BLUE) hosted a Research and Development (R&D) Day shining light on its newly implemented process and manufacturing …
MEI Pharma Inc (NASDAQ:MEIP) just received Breakthrough Therapy Designation for its key pipeline drug pracinostat, anti-tumor molecule inhibitor that combined with azacitidine treats …
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) shares jumped nearly 56% today after the company announced preliminary positive top-line results from its two Phase 3 pivotal studies of …
In a research report published Friday, Wedbush analyst David Nierengarten maintained a Neutral rating on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) with a $2.
In a research report released Friday, Wedbush analyst David Nierengarten reiterated a Neutral rating on MEI Pharma Inc (NASDAQ:MEIP) with a $3 price target, …
Wedbush analyst David Nierengarten was out with some neutral comments on NPS Pharmaceuticals (NASDAQ:NPSP), following the news that the company’s Natpara has been approved by the FDA to …
In a research report released yesterday, Wedbush analyst David Nierengarten reiterated an Outperform rating on Bluebird Bio (NASDAQ:BLUE) with a price target of …